Loading...
•
Jun 30, 2024
Bausch Health Q2 2024 Earnings Report
Bausch Health announced its second quarter results, showcasing revenue and adjusted EBITDA growth and raised full-year guidance.
Key Takeaways
Bausch Health reported a strong second quarter with an 11% increase in consolidated revenues to $2.40 billion and a 10% increase in adjusted EBITDA to $798 million. The company also raised its full-year revenue and adjusted EBITDA guidance, reflecting confidence in its growth strategy and product portfolio.
Consolidated revenues reached $2.40 billion, up 11% year-over-year.
Adjusted EBITDA increased by 10% to $798 million.
GAAP Net Income Attributable to Bausch Health Companies Inc. was $10 million.
Full-year revenue and Adjusted EBITDA guidance were raised.
Bausch Health
Bausch Health
Bausch Health Revenue by Segment
Revenue by Segment
Bausch + Lomb/International Revenue
CapyFin.comSalix Revenue
CapyFin.comDiversified Products Revenue
CapyFin.com Forward Guidance
The Company raised its consolidated full-year Revenue guidance to $9.400 - $9.650 billion and Adjusted EBITDA guidance to $3.21 - $3.36 billion.
Positive Outlook
- Revenue (in Billions): $9.400 - $9.650
- BHC (excl. B+L) Revenue (in Billions): $4.700 - $4.850
- B+L Revenue (in Billions): $4.700 - $4.800
- Organic growth vs. Prior Year: 2%-5%
- Adjusted EBITDA (in Billions): $3.21 - $3.36
Revenue & Expenses
Visualization of income flow from segment revenue to net income